REPLIGEN CORP
RGENNASDAQTrading Snapshot
- Day Range
- $173.54 β $185.88
- 52-Week Range
- $100.99 β $198.87
- Volume (shares)
- 1,447,759
- Avg Volume (shares)
- β
- Shares Outstanding
- 63.5M
- Next Earnings
- 2027-02-22
Fundamentals Snapshot
- Annual Revenue
- $738M
- Last Q Revenue
- $204M
- P/E Ratio
- 268.5
- P/S Ratio
- 14.2x
- EPS (TTM)
- $0.73
- Dividend Yield
- β
- Dilution (1yr)
- +0.8%
REPLIGEN CORP
RGENAbout REPLIGEN CORP
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

What Repligen (RGEN) Said on Its Q3 Earnings Call
Repligen NASDAQ: RGEN reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises

Conestoga Small Cap Composite Q3 2026 Portfolio Activity
The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, De

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.46 per share a year ago.

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife acquisition, which fast-tracks Repligen's leadership and offering in high-growth cell therapy market Ra

Baron Health Care Fund Q3 2026 Top Contributors And Detractors
TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guid